FDA godkänner Travere Therapeutics FILSPARI för FSGS

13 april 2026

Rapporterad av AI

Den amerikanska läkemedelsmyndigheten FDA har godkänt FILSPARI, utvecklat av Travere Therapeutics, som den första medicinen för fokalsegmentell glomeruloskleros (FSGS). Travere meddelade godkännandet den 13 april 2026. Företagsledningen höll en konferens för en verksamhetsuppdatering samma kväll för att diskutera milstolpen.

Travere Therapeutics meddelade tidigare den 13 april 2026 att FDA godkänt FILSPARI för patienter med FSGS. Enligt företaget är läkemedlet den första godkända behandlingen för detta njurtillstånd. Ett pressmeddelande och presentationsmaterial finns tillgängligt på Travers webbplats för investerare. President och CEO Eric Dube ledde diskussionen under konferenssamtalet, med flankering av Chief Medical Officer Jula Inrig och Chief Commercial Officer Peter Heerma för förberedda kommentarer. Chief Research Officer William Rote och Chief Financial Officer Chris Cline deltog i frågestunden. Analytiker från firmor som Leerink Partners, JPMorgan Chase, Guggenheim Securities, Wedbush Securities, TD Cowen, Cantor Fitzgerald, Wells Fargo Securities, Jefferies, Citigroup, BofA Securities och Stifel deltog i samtalet. Nivi Nehra, Vice President of Corporate Communications and Investor Relations, inledde mötet.

Relaterade artiklar

Illustration of a doctor discussing positive kidney treatment results with a patient using digital graphs.

Finerenone slows kidney decline in non-diabetic CKD trial; pooled analysis suggests broader benefits across CKD

8 juni 2026 Rapporterad av AI Bild genererad av AI Faktagranskad

New data presented at the European Renal Association’s 63rd Congress in Glasgow and published in three major medical journals found that finerenone slowed kidney-function decline in adults with chronic kidney disease (CKD) without diabetes and reduced the risk of a combined kidney-and-cardiovascular outcome. A separate pooled analysis that combined results across finerenone studies also reported fewer kidney and heart-failure events in a broader CKD population.

Syntara reports positive FDA feedback on amsulostat trial

Syntara Limited held a shareholder webinar on April 29 to discuss FDA feedback on its proposed Phase IIb trial for amsulostat in myelofibrosis, along with a capital raise and quarterly report. CEO Gary Phillips highlighted the agreed path forward with regulators. The company lodged its Appendix 4C quarterly with the ASX.

Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment

13 maj 2026 Rapporterad av AI

A Japanese health panel has approved national health insurance coverage for Sumitomo Pharma's Amchepry, an iPS cell-derived treatment for Parkinson’s disease. The move makes it the world's first commercialized medical product from iPS cells.

Hälsa

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Affärer

Medartis hosts investor event in Basel on hand products

Europa

SpectraCure launches rights issue to finance studies

Pemafibrate and telmisartan cut liver fat in MASLD animal models, study suggests

Researchers in Barcelona report that the lipid drug pemafibrate and the blood-pressure medicine telmisartan reduced diet-induced liver fat in rats and in a zebrafish model of fatty liver disease, with a half-dose combination performing as well as full doses of either drug alone. The work, published in Pharmacological Research, also describes a role for the PCK1 protein in telmisartan’s liver effects and argues that clinical trials would be needed to confirm any benefit in people.

Caribou Biosciences presents car-t updates at healthcare conference

16 maj 2026 Rapporterad av AI

Caribou Biosciences discussed progress on its off-the-shelf CAR-T therapies during a presentation at the Bank of America Global Healthcare Conference on May 13. Chief executive Rachel Haurwitz highlighted Phase I data for two programs that target lymphoma and multiple myeloma.

14 juni 2026 20:53